ArticleTransplant international : official journal of the European Society for Organ Transplantation2022
Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review.BMC nephrology · 2026Article
- Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation.Clinical kidney journal · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective.Clinical kidney journal · 2025Article
- Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide - a case report.Journal of nephrology · 2025Article
- What is new in the pathogenesis and treatment of IgA glomerulonephritis.World journal of nephrology · 2024Review
- Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy.Clinical kidney journal · 2024Article
- Systemic and targeted steroids for the treatment of IgA nephropathy.Clinical kidney journal · 2023Review
- Immune abnormalities in IgA nephropathy.Clinical kidney journal · 2023Review
- IgA Nephropathy: Current Treatment and New Insights.Antibodies (Basel, Switzerland) · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.